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Hodgkin’s disease (HD) is a neoplasm that was projected
to afflict more than 7200 people in the U.S. in 1999 [1].
Although HD is associated with long-term survival after
standard therapy in the majority of cases, a subset of patients
eventually succumbs: 1300 patients were expected to die of
HD in 1999. High-dose therapy (HDT) and autologous
hematopoietic cell transplantation (AHCT) have been used
in various settings in HD with the goal of prolonging dis-
ease-free survival (DFS) and overall survival (OS). This arti-
cle will review the use of AHCT in HD, including pertinent
clinical data, the source of stem cells, and preparative regi-
mens with associated toxicities. We hope to impress on the
reader the continued need for formal clinical trials to effi-
ciently and correctly determine the role for AHCT in HD.
HODGKIN’S DISEASE CLINICAL RESULTS
R e l a psed or Refractory Disease
The majority of patients with HD will be cured with
conventional chemotherapy, radiation, or both [2,3]. Unfor-
t u n a t e l y, patients who relapse after primary chemotherapy
( o n e - t h i rd) or are re f r a c t o ry to initial therapy (one-fourt h )
have a minimal chance for long-term survival with standard
salvage therapy. HDT and AHCT have been applied to this
g roup of patients with the goal of eradicating HD. The fir s t
series of HDT and AHCT as salvage therapy for re l a p s e d
and re f r a c t o ry HD patients were re p o rted almost 15 years
ago [4-6]. Those studies included heavily pre t reated patients,
many with pro g ressive disease at the time of HDT. Although
the early mortality was as high as 50%, the outcomes were
encouraging, with approximately one-third of patients
remaining disease-free at a short follow-up of 1 to 2 years.
Since the initial re p o rts, numerous phase 1 and 2 studies of
HDT and AHCT have shown evidence for prolonged re m i s-
sion with marked reduction in tre a t m e n t - related mort a l i t y,
although late relapses have been observed [7-26]. Table 1
summarizes results of selected recent series of HDT and
AHCT in relapsed and re f r a c t o ry HD. These studies are
notable for a heterogeneous patient population of early and
late relapses, single and multiple relapses, and chemosensi-
tive and chemoresistant relapses as well as patients without a
prior complete remission. The median follow-up ranged
f rom <2 years to 6.5 years, with estimated disease contro l
ranging broadly from 25% to 70%.
Prognostic factors. Prognostic factors described for relapsed
or refractory HD patients undergoing HDT and AHCT are
summarized in Table 2. Using these prognostic feature s ,
investigators have published prognostic indices that m a y
p redict the outcome of patients based on the number of risk
factors present at the time of relapse or HDT [18,24,27].
Wheeler et al. [24] found progressive disease at the time of
HDT, more than 1 extranodal site of relapse, and poor per-
f o rmance status to correlate with the outcome of 102
patients with relapsed/refractory HD treated with HDT and
AHCT. The 3-year actuarial OS was 82%, 56%, and 19%
for patients with 0, 1, or ≥2 of these risk factors, re s p e c-
tively. A similar model was reported by Horning et al. [18]
in 119 patients with re l a p s e d / re f r a c t o ry HD, identifying B
symptoms (systemic symptoms such as drenching night
sweats and weight loss), disseminated disease with bone
marrow (BM) or pulmonary involvement, and greater than
minimal disease at the time of HDT as high-risk feature s .
Freedom from progression (FFP) was 85%, 57%, 41%, and
<20% when there were 0, 1, 2, or 3 risk factors pre s e n t ,
respectively, at the time of HDT (Figure 1). These indices
provide clues for therapeutic initiatives in addition to prog-
nostic information.
Of the prognostic factors in relapsed or re f r a c t o ry
patients receiving HDT and AHCT, the least consistent has
been length of remission. Reece et al. [28] reported a signifi-
cantly superior pro g re s s i o n - f ree survival (PFS) in first-
relapse patients with a remission duration of 12 months or
m o re (85%, n = 23 patients) compared with those with
remission duration <12 months (48%, n = 35 p a t i e n t s ) .
Remission duration did not have an impact on PFS or OS in
87 first-relapse patients treated with HDT and AHCT
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re p o rted by Fung et al. [29] or in 60 first-relapse patients
receiving HDT re p o rted by Yuen et al. [30]. A definitive
conclusion regarding remission duration as a prognostic fac-
tor for HDT and AHCT is limited by short median follow-
ups and small numbers.
Historical comparisons. An update of relapsed or refractory
patients treated at the National Cancer Institute (NCI) with
conventional salvage therapy offered a historical comparison
of survival after prolonged follow-up of 107 patients treated
with nitrogen mustard, vincristine, procarbazine, and pred-
nisone (MOPP) or MOPP-containing salvage re g i m e n s
[31]. The projected 20-year OS was 17% and, as in the orig-
inal NCI report, the length of initial remission had a signifi-
cant impact on outcome [32]. The complete remission (CR)
rate and OS were 79% and 24%, respectively, at 11 years for
patients with remission duration >1 year and 49% and 11%,
re s p e c t i v e l y, for patients with remission duration ≤1 year.
Although the projected 20-year DFS was 45% for long-
remission patients, nonrelapse mortality due to secondary
leukemia and other tre a t m e n t - related complications cur-
tailed their survival. These data are primarily of historical
interest because they reflect an era when doxorubicin-con-
taining combinations were not standard in primary therapy
or, as in this review, in salvage treatment. A more optimistic
outlook for the HD patient with more than a 12-month CR
t reated with standard salvage therapies was re p o rted fro m
Milan, with 5-year FFP of 51% and OS of 65% [33]. A
recent update of the Milan study patients failing MOPP-
ABVD (MOPP and adriamycin, bleomycin, vinblastine, and
dacarbazine [ABVD]) therapy showed an 8-year OS of 27%,
with length of remission affecting outcome (28% OS for
≤12 months versus 54% OS for >12 months) [34].
As noted above, Yuen et al. [30] did not find remission
duration to be a predictor of outcome in 60 first-re l a p s e
patients receiving HDT and AHCT. However, upon histor-
ical comparison to a matched control group receiving con-
ventional salvage therapy, the patients with remission dura-
tion ≤12 months had a significantly improved event-fre e
survival (EFS) (56% versus 19%, P < 0.01) and PFS (58%
versus 19%, P < .01) after HDT and AHCT. A similar dif-
f e rence between conventional therapy and HDT was not
seen in the patients with remission duration of >12 months.
In neither remission duration cohort was OS significantly
different between conventional salvage therapy and HDT.
Randomized trials. T h e re have been 2 randomized studies
in relapsed or re f r a c t o ry patients comparing standard - d o s e
therapy to HDT using the drugs BCNU, etoposide, cytosine
arabinoside, and melphalan (BEAM) [35,36]. The first trial
was published by Linch et al. [35] using the same chemother-
apeutic agents for each arm but employing diff e rent doses
(mini-BEAM versus BEAM). Twenty patients were random-
ized to each arm, meeting the eligibility criteria of no history
of CR, ≤1 year initial CR duration, or failure of ≥2 lines of
therapy at relapse. EFS was superior after BEAM at 53%
c o m p a red with mini-BEAM at 10% (P = .025). OS, however,
was not statistically diff e rent (75% versus 55%, re s p e c t i v e l y )
owing to small numbers and the impact of subsequent trans-
plantation. The second trial was re p o rted in abstract form by
the German Hodgkin’s Disease Study Group (GHSG) and
the Working Party of the European Group for Blood and
M a rrow Transplantation (EBMT) [36]. Relapsed HD
patients <60 years old were stratified by their relapse status
and randomized to receive 4 courses of DexaBEAM (dexa-
methasone and a mini-BEAM variation) versus 2 courses of
DexaBEAM followed by BEAM and AHCT. Only patients
with a CR or partial remission (PR) to 2 courses of Dexa-
BEAM proceeded on protocol with their previously random-
ized therapy. Of the 161 originally randomized patients, 123
p roceeded to all 4 courses of DexaBEAM or HDT and
Table 1. High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (HCT) for Relapsed/Refractory Hodgkin’s Disease*
Survival
Receiving Median †Event-, ‡Disease-,
Pre-HCT Follow-Up, First Early or §P r o g r e s s i o n - Overall,
Reference N Cytoreduction, % Regimen mo Relapse, % Mortality, % Free, % %/y
Rapoport et al. [16] 47 >50 BEAC 20 — 17 49† —
Yahalom et al. [14] 47 100 TLI, VP-16/CY 40 25 17 50‡ —/6
Chopra et al. [13] 155 72 BEAM 24-36 34 10 50§ 55/5
Reece et al. [10] 56 40 CBV 42 36 21 47† 53/5
Wheeler et al. [24] 102 100 CBV 48 46 12 42§ 65/3
Arranz et al. [22] 47 >90 CBV 36 50 9 34§ 52/7
Nademanee et al. [17] 85 99 TBI/VP-16/CY, CBV 28 51 13 58‡ 75/2
Bierman et al. [12] 128 >25 CBV 77 65 4 25§ 45/4
Horning et al. [18] 119 100 TBI/VP-16/CY, CBV, 40 73 5 48† 52/4
CCNU/VP-16/CY
*BEAC indicates BCNU, etoposide, and cytosine arabinoside; BEAM indicates BCNU, etoposide, cytosine arabinoside, and melphalan; CBV indicates
cyclophosphamide, BCNU, and etoposide; CY, cyclophosphamide; TBI, total-body irradiation; TLI, total lymphoid irradiation; VP-16, etoposide.
Table 2. Prognostic Factors for Relapsed/Refractory Hodgkin’s Disease and
Autologous Hematopoietic Cell Transplantation (HCT)
Prognostic Factor Reference
Performance status at relapse [10,12,25]
Disease status at time of HCT [18,21,22,23,26,28,42]
Chemoresponsiveness at relapse [14,21,24,30]
Remission duration [28]
Tumor bulk at relapse [13,16,26,28]
Extranodal relapse [17,18,21,24,28]
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A H C T. Failure to complete the full course of therapy in the
majority of cases was due to life-threatening or fatal toxicity
f rom the previous therapy or less than a PR to the first 2
courses of DexaBEAM. In an i n t e n t i o n - t o - t reat analysis, with
a 34-month median follow-up, there was longer time to tre a t-
ment failure (TTF) for all chemosensitive patients (P = .02) as
well as subgroups of early or late first relapse (P = .04 each)
with HDT and AHCT. OS was not significantly diff e re n t
with limited follow-up. In an evaluation of all eligible
patients, re g a rdless of chemosensitivity, there was no diff e r-
ence in TTF or OS.
The above phase 3 studies suff e red from lack of patient
i n t e rest for randomization and were closed before the orig-
inal accrual goals were met. The small numbers in each
trial resulted in suboptimal power. Unfort u n a t e l y, as in the
r a ndomized AHCT trial for relapsed or re f r a c t o ry non-
H o d g ki n ’s lymphoma (NHL) [37], one-third or more of
patients initially enrolled were unable to proceed with the
planned therapy because of pro g ressive or inadequately
responsive disease, re g i m e n - related toxicity, or patient
refusal. Finally, when crossover from 1 arm to another after
f a i l u re of initial therapy is allowed, the survival benefits of 1
t reatment arm over another become ill-defined, at best.
The superior salvageability may explain similar OS despite
i m p roved EFS or TTF in the chemosensitive patients
receiving HDT and AHCT.
P r i m a ry re f r a c t o ry disease. P r i m a ry induction failure
(PIF) and primary re f r a c t o ry disease are terms used inter-
c h a n g e a b l y, and their definitions may vary. PIF and pri-
m a ry re f r a c t o ry disease may be considered simply as never
Figure 1. Freedom from progression in 119 patients with recurrent or refractory Hodgkin’s disease treated with high-dose therapy and autografting according to
a number of unfavorable prognostic factors. See text for description of prognostic factors. A. No prognostic factors, n = 46, ––––––; 1 prognostic factor, n = 39, 
- - - - - ; 2 prognostic factors, n = 23, – · – · – · ; 3 prognostic factors, n = 6, ––––––. B. No unfavorable prognostic factors, n = 46, ––––––; 1 to 3 prognostic factors, 
n = 68, - - - - - . Reprinted with permission [18].
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having achieved CR after induction therapy. Before the
c u rrent radiologic technology, residual radiologic findings
w e re not frequently detected, and the term CR was more
readily defined. It is now known, however, that re s i d u a l
radiologic abnormalities often remain after adequate
induction therapy for HD, and only with a biopsy or radio-
logic evidence of pro g ression can one determine that
active disease is present—that is, re f r a c t o ry disease [38,39].
A current definition of PIF or primary re f r a c t o ry disease
should encompass pro g ression of disease during induction
t reatment as well as a partial or transient response (60 to
90 days) to induction therapy. The most rigorous studies
would include patients with persistent radiologic abnor-
malities only if there was biopsy-proven evidence of dis-
ease or clear pro g ression by radiologic evaluation.
Patients with PIF or primary refractory HD historically
have not done well with conventional salvage therapy. The
median OS was 16 months for patients with refractory HD
t reated at the NCI with standard therapy [31]. The Milan
series re p o rted an 8-year OS of 8% in patients failing
MOPP-ABVD [34]. Table 3 summarizes selected reports of
induction failure HD treated with HDT and AHCT [13,14,
22,30,40-45]. As in the series of re f r a c t o ry and re l a p s e d
patients, the follow-up was short, ranging from 2 to 6 years,
with an estimated OS of 35% to 60%. The recent update of
29 primary re f r a c t o ry patients treated at Stanford U n i v e r-
sity has a median follow-up of 65 months with a 4-year
EFS of 49.5% (Figure 2) [44]. Although these results are
p romising, it is important to be aware of patient selection
bias in HDT results. In the Stanford study, for instance, the
majority of the patients proceeding to HDT did have
c h e m o t h e r a p y - responsive, minimal disease just before
H D T. As suggested by the prognostic factors in Table 2,
chemosensitivity or minimal disease status may have
selected a better prognostic group.
No randomized studies have specifically compare d
HDT and conventional salvage therapy in primary re f r a c-
tory patients; however, some studies have conducted histori-
cal comparisons with conventionally treated matched controls
[30,42,46]. Yuen et al. [30] found that EFS and FFP were
superior after HDT compared with standard therapy, but
OS was not significantly diff e rent (Figure 3). The Société
Française de Greffe de Moëlle (SFGM) [42] also reported a
comparison of HDT and conventionally treated matched
c o n t rols with a trend for improved OS after HDT (P =
.058). Josting et al. [46] recently published a re t ro s p e c t i v e
analysis of 67 patients with primary progressive HD t re a t e d
with HDT and AHCT or conventional salvage t h e ra p y. Of
note, only one-third of the eligible patients proceeded to
AHCT (reasons for not proceeding were chemotherapy-
resistant  disease, patient refusal, and salvage
t re a t m e n t – related toxicity). The estimated 5-year OS was
53% (mean OS, 56 months) in the 25 patients re c e i v i n g
HDT and AHCT compared with 0% (mean OS, 11
months) in the remaining patients receiving only conven-
tional salvage therapy. Chemosensitivity and the use of
HDT and AHCT were both significant factors associated
with improved TTF (P = .0001 and .031, respectively) and
OS (P = .0005 and .039, respectively).
Timing of HDT and AHCT. The ideal time to pursue
HDT and AHCT in relapsed or refractory HD is not well-
defined. The evidence from historical comparisons as well as
the 2 randomized trials would suggest the greatest benefit in
disease control after HDT to be among patients with refrac-
t o ry disease or remission duration ≤12 months. In the
relapsed patient with a remission >12 months, comparisons
of long-term morbidity and OS associated with salvage ver-
sus HDT and AHCT after doxorubicin-containing induc-
tion regimens that are now standard first-line HD therapy
require extended follow-up of the completed phase 2 studies
[31,47]. Prognostic indices as described above may be
important in identifying the patients who are most and least
likely to do well after HDT and AHCT. The relapsed or
re f r a c t o ry HD patient with an estimated OS of <20%
despite HDT clearly needs an approach different from the
current HDT and AHCT strategies.
Table 3. High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (HCT) for Induction Failure Hodgkin’s Disease*
Survival
Receiving Median †Event-, ‡Disease-,
Pre-HCT Follow-Up, Early or §Progression- Overall,
Reference N Cytoreduction, % Regimen mo Mortality, % Free, % %/y
Reece et al. [40] 30 Majority CBV ± P 3.6 years 17 42† 60/5
Bierman et al. [41] 44 — CBV — — 22‡ —
Chopra et al. [13] 46 — BEAM 2-3 years — 33‡ —
Yahalom et al. [14] 28 All TLI, VP-16/Cy 40 months — 33§ —/6
Sweetenham et al. 175 — Half BEAM, half CBV 73 months 14 32‡ 36/5
(EBMT) [45] and other
Horning [44] 29 All TBI/VP-16/Cy, CBV 65 months — 49.5† —/4
André et al. (SFGM) [42] 86 — BEAM, CBV 29 months 8 25† 35/—
Arranz et al. [22] 47 More than half CBV 3 years — 34‡ 52/7
Lazarus et al. (ABMTR) [43] 122 Majority One-third CBV 28 months 12 38‡ 50/3
and other
Josting et al. [46] 25 All BEAM, CBV 59 months — — 53/5
*BEAM indicates BCNU, etoposide, cytosine arabinoside, and melphalan; CBV indicates cyclophosphamide, BCNU, and etoposide; CBV ± P indi-
cates cyclophosphamide, BCNU, and etoposide with or without cisplatin; CY, cyclophosphamide; TBI, total-body irradiation; TLI, total lymphoid
irradiation; VP-16, etoposide. 
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P r i m a r y Therapy
The majority of patients with advanced HD are cure d
with standard chemotherapy,  with the one-third of
patients suffering relapse having a marginal chance for
l o n g - t e rm survival after conventional therapy and a 50%
chance after AHCT [2,3,46]. Survival is limited by pri-
m a ry re f r a c t o ry disease, treatment failure after relapse, or
n o n relapse complications. The potential success of HDT
and AHCT is limited to patients with responsive disease
and those who do not have excessive therapy-related toxi-
cities or comorbid conditions. Incorporating HDT and
AHCT as an intensification or consolidation measure in
first remission may allow the treatment of more high-risk
HD patients, possibly improving disease control as well as
l o n g - t e rm survival [23,48-52].
Ta rgeting at diagnosis the group of advanced HD
patients with a poor prognosis would be the ideal appro a c h
for the use of HDT and AHCT as up-front therapy. Sev-
eral centers have published prognostic factors and corre-
sponding scores or indices to assist in predicting the high-
risk HD patient at presentation [53-55]. The high-risk
f e a t u res have included low hematocrit, high lactate dehy-
d rogenase (LDH) levels, age ≥45 years, advanced-stage dis-
ease, low lymphocyte count, high ery t h rocyte sedimenta-
tion rate, and bulky mediastinal disease. More recently the
I n t e rnational Prognostic Factors Project on Advanced HD
[56] proposed a prognostic score predictive of FFP and OS
after standard therapy based on analysis of >5000 patients.
The 7 risk factors identified and their correlation with FFP
and OS are summarized in Table 4. Although these feature s
s t r a t i fied patients with advanced HD, they did not identify
a sizeable group with a >50% risk for relapse, suggesting
the need for biological clues.
C a rella et al. [48] first re p o rted the use of HDT and
AHCT in 15 high-risk first-CR HD patients and com-
p a red them with a historically matched control group who
achieved CR but refused HDT. All patients had Ann
Arbor stage IVB disease [57] with 2 or more extranodal
sites, increased LDH levels, bulky mediastinal disease, and
no BM involvement. After an initial median follow-up of
36 months, the PFS was 87% after HDT and AHCT
c o m p a red with 33% for the treatment controls. A subse-
quent update in 22 patients with 86 months’ median fol-
low-up re p o rted PFS of 77% and 33%, respectively [58].
The EBMT with the GHSG [49] published, in abstract
f o rm, a re t rospective review of 56 first-CR HD patients
who received HDT and AHCT, comparing them with
1 6 8 matched controls receiving standard therapy. A l t h o u g h
these investigators found a significantly longer DFS but
not OS after HDT and AHCT, the statistical significance
was similar for both outcomes (DFS, P = .0497;  OS,
P = .05). Other re t rospective reviews from the SFGM [23]
and the Spanish Cooperative Group (GEL-TAMO) [52]
w e re  re p o rted with median follow-up of 46 and 30
months, re s p e c t i v e l y. The patients in the GEL-TA M O
re p o rt had high-risk features re t rospectively identified
including 2 or more extranodal sites, bulky mediastinal
Figure 2. Event-free survival of 29 patients treated with myeloablative therapy and autologous transplantation for refractory Hodgkin’s disease at Stanford
University from 1988 to 1995. Patients had progressed during induction chemotherapy (n = 17), had persistent disease at the conclusion of therapy (n = 14), or
had progressive disease within 60 days of completing treatment (n = 8). Estimated EFS at 4 years was 49.5% (95% confidence limits, 39.6%, 59.3%). Reprinted
with permission from Horning SJ. Primary refractory Hodgkin’s disease [review]. Ann Oncol. 1998;9(suppl 5):S97-S101.
Table 4. Prognostic Score for Advanced Hodgkin’s Disease*
Number Freedom From Overall
Prognostic Factors of Factors Progression, % Survival, %
Serum albumin <4 g/dL 0 84 ± 4 89 ± 2
Hemoglobin <10.5 g/dL 1 77 ± 3 90 ± 2
Male sex 2 67 ± 2 81 ± 2
Stage IV disease 3 60 ± 3 78 ± 3
Age ≥45 years 4 51 ± 4 61 ± 4
White blood cell count ≥5 42 ± 5 56 ± 5
≥ 1 5 , 0 0 0 / m m 3
Lymphocyte count
<600/mm 3 or <8% of 
white blood cell count
*Reprinted with permission [56].
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disease, bone marrow involvement, and advanced Ann
Arbor stage, whereas the SFGM participating centers’ cri-
teria were not described. Although the SFGM series (130
patients) included first CR and PR patients, EFS was simi-
lar to that of the GEL-TAMO series (27 patients), 74%
and 78%, re s p e c t i v e l y, with OS of 81% and 93%, re s p e c-
t i v e l y. Of note, DFS and OS were not significantly diff e r-
ent between first-PR and first-CR patients in the SFGM
study (5-year OS 83% and 76%, re s p e c t i v e l y, and DFS
76% and 70%) with the definition of PR being >50%
reduction in tumor mass without criteria re g a rding evi-
dence of pro g ressive or residual disease.
A prospective phase 2 trial was conducted by Nadema-
nee et al. [59] in poor-risk advanced-stage HD during fir s t
CR or PR. Patients in first CR with 3 or more of the fol-
lowing poor-risk features were off e red HDT and AHCT:
stage IV disease with BM or >1 extranodal site involved,
bulky mediastinal mass greater than one-third of mediasti-
nal/thoracic ratio or bulky mass >10 centimeters, B symp-
toms, and elevated LDH level. Patients with any of the
poor prognostic factors who had achieved only a PR or
re q u i red 2 or more combination chemotherapy regimens to
achieve a CR were also eligible to proceed to AHCT.
Twenty patients received HDT and AHCT (14 CR and
6 PR, all with evidence of persistent disease by biopsy, gal-
lium scan, or bone scan). At a median fol low-up of
4 2 . 8 months, the DFS and OS were 100%.
T h e re has been 1 pre l i m i n a ry re p o rt of a randomized
trial conducted by the EBMTR and Australia-New Zealand
Lymphoma (ANZLG) Interg roup HD01 [50]. High-risk
HD patients were identified at diagnosis based on the fea-
tures described by Straus et al. [54]. Patients were evaluated
for response after 4 cycles of ABVD, with those achieving a
PR or CR eligible for randomization to 4 additional cycles
of ABVD or HDT and AHCT. At the time of the prelimi-
nary report with 55 enrolled patients, no major treatment-
related toxicities were associated with HDT.
Although the above re p o rts of HDT and AHCT in
f i r s t - remission HD patients have shown encouraging PFS
and OS, the number of patients is small, the data are prelim-
i n a ry, and the studies are difficult to compare to standard
therapy without the nonbiased approach of an intention-to-
treat analysis in a randomized trial. A cooperative group trial
via the Southwestern Oncology Group is currently enrolling
patients with advanced HD and 3 to 7 of the risk factors
identified by the International Prognostic Factors Pro j e c t
on Advanced HD [56] (Table 4). Patients are randomized to
receive ABVD for 8 cycles versus 4 cycles followed by HDT
and AHCT. At this time, however, HDT and AHCT for
HD patients in first remission should be pursued only in the
setting of clinical trials.
PRETRANSPLANT CYTOREDUCTION
Patients with relapsed or refractory HD typically receive
c y t o reduction before HDT and AHCT. This practice is
supported by several centers describing minimal disease sta-
tus or chemoresponsiveness before HDT as factors correlat-
ing with a better outcome [14,18,21-24,26,30,42]. Chopra et
al. [13] as well as Bierman et al. [60], however, have reported
that patients with an untested relapse had superior outcomes
versus patients with either chemosensitive or chemoresistant
disease before HDT. Radiation therapy has been used as a
method of pretransplant debulking, but chest radiation,
especial ly in combination with a BCNU-containing
p re p a rative regimen, has been associated with an increased
incidence of pneumonitis [10,15,17,18,24]. Whether cyto-
reduction by chemotherapy or radiation is simply a test of
c h e m o responsiveness or actually has an additive effect on
control of disease is not known.
CONSOLIDATIVE RADIOTHERAPY
I n v o l v e d - field radiotherapy (IF-RT) has been incorpo-
rated into transplant regimens with the goal of pre v e n t i n g
relapse at involved sites. There is evidence that IF-RT alters
the relapse pattern after HDT, but it has not influenced OS
[61,62]. Mundt et al. [61] found a decreased relapse rate at
the site of prior disease for patients receiving IF-RT versus
patients who did not. Poen et al. [62] noted an impro v e d
PFS and a trend for improved OS for patients re c e i v i n g
I F -RT, but only in patients with stage I to III disease. The
Figure 3. Survival in patients failing induction therapy who subsequently received either high-dose therapy and autografting (n = 13, –––––) or conventional
salvage therapy (n = 26, – – – – ). A. Overall survival (log rank P > .2). B. Event-free survival (log rank P = .01). Reprinted with permission [30].
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selection of patients receiving IF-RT may be an important
factor in the interpretation of these results, given that
patients eligible for consolidative RT are those with limited,
p reviously unirradiated disease. Conversely, many of the
patients receiving RT had bulky or chemoresistant disease.
Although the use of RT in transplantation is theore t i c a l l y
attractive and some data support its application, the incre-
mental benefit of RT has not been defined.
HIGH-DOSE REGIMENS
Many high-dose regimens have been used as pre p a r a-
tion for AHCT. The more common combinations are iden-
tified in Tables 1 and 3. No randomized trials have com-
p a red the diff e rent  preparative  regimens, but single
institutions have published retrospective or historical com-
parisons [9,15,17,63,64]. As one reviews the experience with
the various preparative regimens, it is apparent that they dif-
fer more in toxicity profiles than in efficacy.
The most widely used drug-only regimen has been
cyclophosphamide (CY), BCNU, and VP-16 (CBV), but at
v a rying doses and schedule of each chemotherapeutic agent
[10,17,18,22,24,65]. The CBV variations have not been
c o m p a red in a randomized setting, but dose-escalation
studies have identified a notable increase in the incidence of
interstitial pneumonitis with increasing doses of BCNU
( c a rmustine 300 mg/m2 to 600 mg/m2) and, in some series,
an increased tre a t m e n t - related mortality [9,15]. Wheeler et
al. [9] re p o rted pneumonitis in 5% of patients re c e i v i n g
4 5 0 m g / m2 BCNU compared with 28% in patients re c e i v-
ing 600 mg/m2 (P = .02). They also noted a correlation with
prior mediastinal radiation and pneumonitis (19% with and
3% without prior radiation). Weaver et al. [15] described a
similar finding with a 23% incidence of grade III or IV pul-
m o n a ry toxicity compared with 0% in patients re c e i v i n g
600 mg/m2 versus 300 mg/m2 BCNU, respectively (P =
.05). Prior exposure to mediastinal radiation affected the
o c c u rrence of idiopathic pulmonary syndrome but only if
the radiation was administered within 3 months of high-
dose therapy (P = .001). Reece et al. [64] recently re p o rted a
historical comparison between CBV (BCNU 600 mg/m2)
and CBV with cisplatin (BCNU 500 mg/m2) in relapsed or
re f r a c t o ry HD. There was no diff e rence in efficacy or pul-
m o n a ry toxicity between the 2 regimens, but there was
de c reased mucosal and liver toxicity in the CBV with cis-
platin regimen. The decreased mucosal toxicity was pre-
sumed to be due to VP-16 administered as a pro l o n g e d
continuous infusion in the cisplatin-containing re g i m e n
rather than twice-a-day dosing for 3 days in the CBV- a l o n e
regimen. With re g a rd to factors affecting the incidence of
re g i m e n - related pulmonary toxicity, they found a signifi-
cant correlation with prior exposure to nitro s o u reas (P =
.001), but not to thoracic radiation. Horning et al. [18]
re p o rted a historical comparison of high-dose CBV versus
CCNU/VP-16/CY and found no diff e rence in toxicity or
s u rvival. Of note, the CCNU/VP-16/CY regimen was
u n d e rtaken in hopes of providing HDT to those patients
with suboptimal pulmonary carbon monoxide diff u s i n g
capacity (DLCO) (<40% predicted) as well as decre a s i n g
the incidence of interstitial pneumonitis associated with
CBV [93].
Total-body irradiation (TBI)-based regimens have been
historically compared with non–TBI-based regimens without
a diff e rence seen in outcome [17,18,63]. Of note, the major-
ity of patients receiving the non–TBI-based regimens did so
because of previous radiation therapy precluding TBI.
T h e re has been a single re p o rt of 1 chemotherapy
preparative regimen having improved survival over another
[66]. This re p o rt was a re t rospective review of 1348 HD
patients receiving AHCT from the EBMTR. The BEAM
regimen had a significantly improved survival over CBV
regimens (P = .0009). However, this study was re p o rted in
abstract form without follow-up published in the 5 years
since the initial report.
As the above information supports, there is no clear
benefit of 1 preparative regimen over another. However, it is
striking that a prospective randomized trial has not been
undertaken. The most notable differences between the vari-
ous regimens are the regimen-related toxicities.
STEM CELL SOURCE
Peripheral blood rather than BM has almost exclusively
become the source of autograft in HD patients. This trend
has been supported by case-controlled and randomized
studies comparing mobilized peripheral blood pro g e n i t o r
cells (PBPCs) to BM [67-69]. The use of mobilized PBPCs
has resulted in more rapid engraftment, shorter hospital
stays, and decreased medical costs compared with the use of
nonmobilized BM. The randomized studies have not shown
a difference in rates of relapse-free survival or OS with the
use of PBPC or BM as the autograft.
The ideal strategy for PBPC mobilization is not clearly
defined. It is known, however, that a greater number of
p rogenitor cells are mobilized when growth factor a d m i n i s t ra-
tion and chemotherapy are combined rather than used sepa-
rately [70,71]. Mobilization is currently carried out thro u g h
g rowth factor administration alone or with myelosuppre s s i v e
c h e m o t h e r a p y. Although the combination of growth factor
administration and chemotherapy enhances mobilization, no
clinical benefit has been documented other than an ability to
complete an adequate PBPC collection in as little as 1 day
[ 7 2 , 7 3 ] .
TOXICITY
Early tre a t m e n t - related mortality (TRM) is defined as
death due to any cause other than disease within 90 to
1 0 0 days from transplantation. TRM after AHCT in HD
has decreased to <10% over the last 10 years [10,13,16,17,
19,24] and, in some re p o rts, to <5% [18,23,27,74]. The
d e c reased early TRM is likely due to multiple factors,
including the use of HDT and AHCT earlier in the course
of HD and improved supportive care. Unfortunately, as has
been seen in the long-term follow-up of relapsed HD
treated with standard salvage chemotherapy, late nonrelapse
morbidity and mortality are not inconsequential. Most
unsettling are secondary acute myelogenous leukemia
(AML) and myelodysplasia (MDS). The projected risk of
AML or MDS at 5 to 7 years after AHCT was 4% to 15%
in 5 series including HD patients [75-79]. The median time
to the histologic diagnosis of AML or MDS after transplan-
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tation was 11 to 45 months. In the SFGM report, 393 auto-
grafted HD patients were matched to 1179 conventionally
treated matched controls [78]. The median follow-up from
the time of HD diagnosis in the AHCT recipients was
51 months; the median follow-up of the ungrafted patients
was not reported. Among the autografted patients, risk fac-
tors associated with secondary malignancies were age
≥40 years and the use of PBPCs rather than BM. There was
no correlation with prior radiation exposure, number or
type of prior chemotherapy regimens, or prior splenectomy.
A 5-year cumulative incidence of secondary malignancies was
10.4% in the autografted patients and 5.2% in the conven-
tionally treated patients. Secondary malignancies included
AML, MDS, and solid tumors (lung, pleural, breast, central
n e rvous system, vulva, and head and neck carcinomas). The
median time to onset of the secondary malignancy after HD
diagnosis was 28 months in the autografted and 50 months in
the conventionally treated patients. The incidence of solid
tumors was greater in the autografted than in the conven-
tionally treated patients, although the incidence of AML or
MDS was the same in this series.
It is important to be aware of the prolonged risk period
for second malignancies in HD patients treated with con-
ventional therapy. Two recently published reports based on
EBMT re g i s t ry data (median follow-up, 14.1 years) and a
collaborative British cohort (median follow-up, 8.5 years) of
surviving HD patients found that the risk for solid tumors
continued to increase more than 15 years after therapy,
w h e reas the risk of AML or MDS plateaued after 5 to
10 years in agreement with the Stanford data [80-82]. These
results indicate that the French registry data may underesti-
mate the cumulative risk of second malignancies, owing to
its relatively short median follow-up. Meanwhile, the prog-
nosis is globally poor for patients with secondary AML or
MDS, as evidenced by a recent re p o rt by Friedberg et al.
[83]. MDS was diagnosed in 41 patients after AHCT for
NHL with an estimated 12-month OS after diagnosis of
MDS of 32%. Thirteen patients underwent allogeneic
HCT and all died, 10 within 100 days of HCT.
S u p p o rted by the above observations, cytogenetic analy-
sis of the BM has become a component of clinical trials as a
routine posttransplantation—and in many transplant centers,
p retransplantation—work-up. In an evaluation of BM cyto-
genetics before HDT at Stanford University, abnormal kary-
otype was an exclusion criterion for transplantation and
thought to be predictive of AML or MDS [84]. In that series
and others, however, patients acquiring abnormal cytogenet-
ics and MDS after HDT had documented normal cytogenet-
ics and histology before HDT [77]. Abruzzese et al. [85]
recently re p o rted the identification of abnormal clones by
flu o rescence in situ hybridization of pretransplant pro g e n i t o r
cells from 9 of 12 patients diagnosed with myelodysplasia
after AHCT for HD (3), NHL (4), breast cancer (4), and
melanoma (1). Only 4 of the 12 patients had cytogenetic
analysis before transplantation, and all 4 were normal. Unfor-
t u n a t e l y, pre-autografting cytogenetics have not been ro u-
tinely obtained or re p o rted, and it will be difficult to com-
ment on the role of cytogenetics in predicting outcome until
they are consistently evaluated before and after transplanta-
tion. In addition, although abnormal cytogenetics have been
o b s e rved upon routine post-autograft BM evaluation in some
patients, not all of them had pro g ressed to clinical or patho-
logic evidence of AML or MDS at the time of the re p o rt [77].
The risk factors associated with secondary malignan-
cies after HDT and AHCT have not been well defined,
although some series have identified consistently age
≥ 4 0 years and, less consistently, PBPCs as the autograft
source [75,76,78,79]. The power of these conclusions, how-
ever, is marginal given the small number of patients acquir-
ing these secondary diagnoses. Appare n t l y, there is a tru e
risk for secondary malignancies in long-term survivors of
HD [78,80,81]. What is not apparent is the incre m e n t a l
impact of AHCT or pre-AHCT therapy on this risk. With
the advent of ABVD therapy replacing MOPP-containing
regimens for initial therapy of HD, the sobering nonrelapse
mortality may become less of a hurdle for the surviving HD
patient [31,34,47].
Quality of life studies have reviewed the impact AHCT
has on the re t u rn to “normal” life for surviving patients [86-
89]. Although these re p o rts have not evaluated HD patients
e x c l u s i v e l y, they have included autologous and autologous
plus allogeneic HCT recipients. Quality of life was good to
excellent for the majority of patients 1 year after transplanta-
tion and improved gradually over time. Sixty percent to 80%
of patients re t u rned to full-time work 1 year or more after
A H C T. Persistent psychologic and social well-being con-
c e rns were frequently associated with fatigue as well as sexual
dysfunction and fertility problems. Unfort u n a t e l y, the major-
ity of HD patients, either male or female, develop gonadal
dysfunction or failure after if not before HDT because of
e x p o s u re to alkylator and occasionally radiation t h e r a p y.
These quality of life issues stress the need for pret r a n s p l a n-
tation and long-term posttransplantation counseling to
e n s u re the patient’s psychological and social re c o v e ry.
MANAGEMENT OF RELAPSE
The therapeutic alternatives for the HD patient relaps-
ing after AHCT are limited. This is a setting where new
d rugs or therapeutic approaches, such as monoclonal anti-
bodies, may be tested. The data reviewing the outcome of
patients with malignancies other than HD treated with
myeloablative allogeneic BM transplantation after failure of
AHCT are dismal. In the majority of cases, survival was lim-
ited not only by disease control, but also by regimen-related
toxicity [90]. Nonmyeloablative allogeneic HCT re g i m e n s
may lessen regimen-related toxicity, although the antitumor
e ffect of the preparative regimen and the donor graft
remains to be seen [91,92]. The realistic goal of therapy for
most patients failing AHCT should be palliation with an
individualized approach to their management.
SUMMARY
The use of HDT and AHCT in Hodgkin’s disease
patients with early relapsed and re f r a c t o ry disease is sup-
p o rted by historical comparisons. In re g a rd to the late
relapsed patient or the newly diagnosed high-risk patient,
the role AHCT plays would ideally be answered by well-
controlled phase 3 trials. A surrogate approach would be the
comparison of AHCT data with well-matched historical
c o n t rols. It is important, however, to be mindful of the
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changes that have occurred in the therapy of the newly diag-
nosed and relapsed HD patient (ABVD replacing MOPP
regimens) and the impact these changes may or may not
have on nonrelapse mortality in the autografted and nonau-
tografted setting. In addition, the incorporation of consis-
tent prognostic factors in any trial design may identify
groups of relapsed or refractory and high-risk HD patients
who may or may not gain benefit from HDT. The most
e ffective and efficient route to answering these tre a t m e n t
questions is enrollment of patients in well-controlled and
well-designed clinical trials.
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